Evidence map›Paper›PMID 42164567›Full record

ReviewCurrent genomics2025

Innovative Applications and Challenges of Isothermal Amplification Technology in miRNA Detection.

Xuebo Li, Zhonglin Zhang, Jian Zhu, Yi Zhang, Yongcan Guo

Abstract readReview
In one paragraph

Review in Current genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuebo LiDepartment of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine, Chengdu, 610000, PR China.
Zhonglin ZhangThe 3RD Affiliated Hospital of Chengdu Medical College,Chengdu Pidu Distriet People's Hospital,Chengdu, 611730, PR China.
Jian ZhuThe 3RD Affiliated Hospital of Chengdu Medical College,Chengdu Pidu Distriet People's Hospital,Chengdu, 611730, PR China.
Yi ZhangThe 3RD Affiliated Hospital of Chengdu Medical College,Chengdu Pidu Distriet People's Hospital,Chengdu, 611730, PR China.
Yongcan GuoNanobiosensing and Microfluidic Point-of-Care Testing, Key Laboratory of Luzhou, Department of Clinical Laboratory, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, 646000, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A class of endogenous non-coding RNAs with a length of roughly 18-25 nucleotides is known as microRNAs (miRNAs). They have been established as the best biomarkers for early cancer diagnosis, molecular subtyping, and prognostic evaluation. They also play important roles in important biological processes like cell proliferation, differentiation, apoptosis, and tumorigenesis through post-transcriptional regulatory networks. Traditional detection technologies (such as quantitative Polymerase Chain Reaction (qPCR), Northern blot, and microarrays) exhibit high sensitivity, yet they rely on expensive thermocycling equipment, involve cumbersome procedures, and are time-consuming, making it difficult to meet the demands of clinical point-of-care testing. In recent years, isothermal amplification technologies, represented by loop-mediated isothermal amplification (LAMP), Rolling Circle Amplification (RCA), Strand Displacement Amplification (SDA), and Exponential Amplification Reaction (EXPAR), have emerged as a research frontier in the field of miRNA detection, by virtue of their advantages including elimination of thermal cycling requirements, fast reaction kinetics, high sensitivity, and simple operation. This study aims to systematically organize the core principles, latest advancements, and integrated innovation patterns of isothermal amplification-based miRNA detection technologies, and provide support for the development of miRNA detection platforms suitable for clinical point-of-care testing.

Indexed as

CRISPR/Casisothermal amplificationmiRNAnanobiosensingtumor biomarkers

Identifiers

PMID42164567
PMCPMC13154243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.